Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Accumulated Expenses: 2011-2024

Historic Accumulated Expenses for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Dec 2024 value amounting to $3.1 million.

  • Lineage Cell Therapeutics' Accumulated Expenses rose 2.00% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 2.00%. This contributed to the annual value of $3.1 million for FY2024, which is 1.83% down from last year.
  • Lineage Cell Therapeutics' Accumulated Expenses amounted to $3.1 million in FY2024, which was down 1.83% from $3.1 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Accumulated Expenses high stood at $22.1 million for FY2021, and its period low was $2.0 million during FY2020.
  • In the last 3 years, Lineage Cell Therapeutics' Accumulated Expenses had a median value of $3.1 million in 2023 and averaged $3.3 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Accumulated Expenses soared by 1,027.41% in 2021 and then crashed by 82.65% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Accumulated Expenses (Yearly) stood at $2.0 million in 2020, then spiked by 1,027.41% to $22.1 million in 2021, then crashed by 82.65% to $3.8 million in 2022, then declined by 18.52% to $3.1 million in 2023, then dropped by 1.83% to $3.1 million in 2024.